Ann: Shareholder Update June Quarter 2016-OBJ.AX, page-45

Hi Andrewk65 and no confusion my end. Just highlighting that you are right in both cases for Nurofen & Voltaren as per Cat Dog's post. Also notice in today's Shareholder Update under Advanced Packaging the following:

'The first potential application for incorporating OBJ’s technologies (DCE) into existing packaging, thereby enhancing a product’s performance, is under evaluation with several of our global FMCG partners.'.........this fits perfectly with Cat Dog's post from the Adelaide Presentation to which I also attended. Who would have thought stating the facts would be considered 'righteousness'.........what a strange world we live in with strange characters at times!